Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461110 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00461110 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants.
The verdict
NCT00461110, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.
Interventions
- DRUG BMS-663513
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461110
The ClinicalTrials.gov registry entry for NCT00461110 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-663513 is the first listed.
NCT00461110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461110 about?
NCT00461110 is a clinical study titled "A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)". The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.
What is the current status of trial NCT00461110?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00461110?
The interventions under investigation include: BMS-663513 (DRUG).
Who is sponsoring clinical trial NCT00461110?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.